Related references
Note: Only part of the references are listed.Inflammation and myeloid malignancy: quenching the flame
Ryan J. Stubbins et al.
BLOOD (2022)
IL-34 Aggravates Steroid-Induced Osteonecrosis of the Femoral Head via Promoting Osteoclast Differentiation
Feng Wang et al.
IMMUNE NETWORK (2022)
Differentiation therapy for myeloid malignancies: beyond cytotoxicity
Ryan J. Stubbins et al.
BLOOD CANCER JOURNAL (2021)
Low-dose IL-34 has no effect on osteoclastogenesis but promotes osteogenesis of hBMSCs partly via activation of the PI3K/AKT and ERK signaling pathways
Jianxiang Xu et al.
STEM CELL RESEARCH & THERAPY (2021)
Emerging roles of IL-34 in health and disease
Iva Lelios et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Evaluation of ERK as a therapeutic target in acute myelogenous leukemia (vol 13, pg 234, 2020)
Ellen Weisberg et al.
LEUKEMIA (2020)
TSC1 regulates osteoclast podosome organization and bone resorption through mTORC1 and Rac1/Cdc42
Song Xu et al.
CELL DEATH AND DIFFERENTIATION (2018)
Preclinical efficacy of MEK inhibition in Nras-mutant AML
Michael R. Burgess et al.
BLOOD (2014)
IL-34 Induces the Differentiation of Human Monocytes into Immunosuppressive Macrophages. Antagonistic Effects of GM-CSF and IFNγ
Etienne D. Foucher et al.
PLOS ONE (2013)